Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients, announces that a presentation of results from its Phase 2 (SKYGGN*) clinical trial, evaluating the efficacy and safety of its drug candidate OCS-01 for the treatment of inflammation and pain following cataract surgery, will be made at the ASCRS 2020 Annual Meeting.
“We look forward to the upcoming presentation of the SKYGGN* results, a trial evaluating OCS-01 as a potential new treatment option for inflammation and pain in patients who have undergone cataract surgery,” said Riad Sherif, M.D., Chief Executive Officer of Oculis. “This is the second randomized Phase 2 trial that we have completed in the last 12 months with OCS-01, a novel eye drop formulation of dexamethasone using SNP, Oculis proprietary nanoparticle formulation technology, and follows the positive results presented earlier this year in patients with Diabetic Macular Edema.”
*SKYGGN is an Icelandic word used to describe someone with good vision and who can see more than others (figuratively).
The presentation, in the form of an electronic poster, will be made available to registered delegates on Saturday, May 16, 2020 on the ASCRS Electronic Posters on Demand website. Details of the presentation: